Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
SAMPLE
Matrix: blood, urine
Sample preparation: Condition a 100 mg 1 mL Bond-Elut C18 SPE cartridge with two 1
mL portions of MeOH, two 1 mL portions of water, and two 1 mL portions of 100 mM
HCl. Condition a CBA-Bond-Elut SPE cartridge with MeOH and water. 1 mL Plasma +
1 mL buffer + 250 ng IS (or 50-500 jxL urine + 500 ng IS), add to the C18 SPE cartridge,
wash with two 1 mL portions of pH 3.4 water, wash with two 1 mL portions of distilled
n-hexane, dry under vacuum for 20-30 min, elute with three 1 mL portions of
chloroform: MeOH 2:1. Evaporate the eluate to dryness, reconstitute with 50 |xL
chloroform: MeOH 50:50 and 50 |xL 2 mg/mL 9-anthryldiazomethane in MTBE, vortex
for a few s, heat at 40 for 90 min, evaporate to dryness, reconstitute with two 100 JJLL
portions of MeCN, add to the CBA SPE cartridge, wash with two 1 mL portions of MeCN,
elute with three 1 mL portions of MeCN: triethylamine 99.8:0.2, evaporate the eluate to
dryness under reduced pressure, reconstitute with 200 |JLL MeCN, inject a 20-50 (xL aliquot. (Prepare 9-anthryldiazomethane as follows. Stir 8.8 g 9-anthraldehyde and 8.5 g
80% hydrazine hydrate (Caution! Hydrazine hydrate is a carcinogen!) in 150 mL EtOH
at room temperature for 3 h, filter off the solid 9-anthraldehyde hydrazone and dry under
vacuum (mp 124-6) (Bull. Chem. Soc. Jpn. 1967, 40, 691). Dissolve 220 mg 9-anthraldehyde hydrazone in 100 mL anhydrous ether, add 800 mg activated manganese dioxide,
follow the reaction by reverse-phase HPLC using MeCN at 0.4 mL/min and UV 254. At
the end of the reaction filter off the manganese and wash it with 20 mL ether, evaporate
the filtrate to obtain 9-anthryldiazomethane (mp 64-6) (Anal.Biochem. 1980, 107, 116
and 1983, 132 456). Prepare activated manganese dioxide as follows. Stir a solution of 20
g potassium permanganate in 250 mL water at room temperature, add 1Og activated
carbon (Nuchar C-190 or C-190N), stir for 16 h, filter (Buchner funnel), wash 4 times
with 50 mL portions of water, dry in air, dry in an oven at 105-110 for 8-24 h
(J.Org.Chem. 1970, 35, 3971).)
HPLCVARIABLES
Column: 125 X 4.6 5 |xm Spherisorb ODS II
Mobile phase: MeCN: MeOH: water 45:40:15 containing 0.24% ammonium perchlorate
and 0.02% triethylamine
Flow rate: 1.6
Injection volume: 20-50
Detector: F ex 360 em 440
CHROMATOGRAM
Retention time: 3.8
Internal standard: [2S-[l[R*(R*)]],2R*]-l-[2-[[(l-carboxy-3-phenyl)propyl]amino]-l-oxopropyl]-octahydro-lH-indole-2-carboxylicacid (PD 110021, Warner-Lambert) (16)
Limit of detection: 5 ng/mL (plasma)
Limit of quantitation: 20 ng/mL (plasma); 100 ng/mL (urine)
OTHER SUBSTANCES
Extracted: metabolites, quinaprilat
Simultaneous: enalapril, enalaprilat
KEYWORDS
plasma; derivatization; pharmacokinetics; SPE
REFERENCE
Hengy, H.; Most, M. Determination of the new ACE-inhibitor quinapril and its active metabolite quinaprilate in plasma and urine by high-performance liquid chromatography and pre-column labelling
for fluorescent-detection. J.Liq.Chromatogr., 1988, 11, 517-530
SAMPLE
Matrix: perfusate
Sample preparation: Add taurocholic acid to perfusate, filter, inject an aliquot.
HPLCVARIABLES
SAMPLE
SAMPLE
Matrix: solutions
HPLCVARIABLES